In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …

The outlook for patients with acute myeloid leukaemia has improved in the past 30 years.
Unlike other cancers, much of this progress is attributable to refinement of supportive …

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults
and accounts for the largest number of annual deaths due to leukemias in the United States …

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults
and accounts for the largest number of annual deaths due to leukemias in the United States …

Postremission therapy in patients with acute myeloid leukemia (AML) may consist of
continuing chemotherapy or transplantation using either autologous or allogeneic stem …

Background Acute myeloid leukemia is the second most common leukemia among United
States adults with a median age of 69 years. We investigated recent clinical practices related …

Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …

Over half of patients diagnosed with acute myeloid leukemia (AML) are 65 years or older.
We examined patient characteristics, treatment patterns, and survival among elderly patients …

Purpose Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)
primarily afflict older individuals. Hematopoietic cell transplantation (HCT) is generally not …

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With
High-Dose Post-Transplantation Cyclophosphamide in Older Adults - PMC Back to Top Skip to …